An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

A prime–boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus

(2010) Yuan-Hui Fu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

(2010) Eric A.F. Simões et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

(2010) Harish Nair et al.   LANCET

Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection

(2010) Sol Kim et al.   VACCINE

Setting priorities for global mental health research

(2009) Mark Tomlinson   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Respiratory Syncytial Virus Vaccine Development

(2009) Yoshihiko Murata   CLINICS IN LABORATORY MEDICINE

Setting Priorities in Global Child Health Research Investments: Guidelines for Implementation of the CHNRI Method

(2009) Igor Rudan et al.   CROATIAN MEDICAL JOURNAL

Respiratory syncytial virus: Back to basics

(2009) W. Paul Glezen   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Newcastle Disease Virus-Like Particles Containing Respiratory Syncytial Virus G Protein Induced Protection in BALB/c Mice, with No Evidence of Immunopathology

(2009) M. R. Murawski et al.   JOURNAL OF VIROLOGY

Research priorities for health of people with disabilities: an expert opinion exercise

(2009) Mark Tomlinson et al.   LANCET

Respiratory syncytial virus market

(2009) Shane Storey   NATURE REVIEWS DRUG DISCOVERY

PHASE-I STUDY MEDI-534, OF A LIVE, ATTENUATED INTRANASAL VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA-3 VIRUS IN SEROPOSITIVE CHILDREN

(2009) Margarita Gomez et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial

(2009) X. Carbonell-Estrany et al.   PEDIATRICS

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV

(2009) Bart Jones et al.   VACCINE

Setting Research Priorities To Reduce Global Mortality from Childhood Diarrhoea by 2015

(2009) Olivier Fontaine et al.   PLOS MEDICINE

Setting Priorities in Global Child Health Research Investments: Universal Challenges and Conceptual Framework

(2008) Igor Rudan et al.   CROATIAN MEDICAL JOURNAL

Climatic, temporal, and geographic characteristics of respiratory syncytial virus disease in a tropical island population

(2008) S. B. OMER et al.   EPIDEMIOLOGY AND INFECTION

Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze

(2008) Lone Graff Stensballe et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mind the gap: equity and trends in coverage of maternal, newborn, and child health services in 54 Countdown countries

(2008)   LANCET

Development of a PIV-vectored RSV vaccine: Preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults

(2008) Roderick S. Tang et al.   VACCINE

Human and bovine respiratory syncytial virus vaccine research and development

(2007) Gilles Meyer et al.   COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES